ULTOMIRIS® mechanism of action
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
In AQP4 Ab+ NMOSD complement activation leads to a continuous chain of destruction which may result in relapses and ultimately physical disability1–3

ULTOMIRIS® specifically targets complement activation, to limit neuronal death, without compromising your patients' entire immune system4
after
before

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
AQP4-IgG+, aquaporin-4 immunoglobulin G positive; C3, complement component 3; C5, complement component 5; CNS, central nervous system; MAC, membrane attack complex; NMOSD, neuromyelitis optica spectrum disorder.
Piatek P, Domowicz M, Lewkowicz N, et al. C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder. Front Immunol. 2018;9:1694. Chamberlain JL, et al. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. J Neurol. 2021;268(5):1643-1664. Kuroda H, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013;254(1-2):178-82. ULTOMIRIS® Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf Last accessed: October 2023. Pittock SJ, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023;93(6):1053-1068. Papadopoulos MC, et al. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14(4):265–277. Rother PR, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–1264. Dutra BG, et al. Neuromyelitis Optica Spectrum Disorders. Radiographics. 2018;38(1):169–193.